

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 July 2021 (01.07.2021)



(10) International Publication Number
WO 2021/130718 A1

(51) International Patent Classification:

C07K 14/005 (2006.01) C12N 15/90 (2006.01)
C12N 15/10 (2006.01) C12P 21/00 (2006.01)

(21) International Application Number:

PCT/IB2020/062436

(22) International Filing Date:

24 December 2020 (24.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/953,405 24 December 2019 (24.12.2019) US
62/960,367 13 January 2020 (13.01.2020) US

(71) Applicant: SELEXIS SA [CH/CH]; chemin des Aulx 14,
1228 Plan-les-Ouates (CH).

(72) Inventors: DUROY, Pierre-Olivier; c/o Selexis SA,
chemin des Aulx 14, 1228 Plan-les-Ouates (CH).
REGAMEY, Alexandre; c/o Selexis SA, chemin des Aulx
14, 1228 Plan-les-Ouates (CH). ARIB, Ghislaine; c/o
Selexis SA, chemin des Aulx 14, 1228 Plan-les-Ouates
(CH). LE FOURN, Valerie; c/o Selexis SA, chemin
des Aulx 14, 1228 Plan-les-Ouates (CH). CALABRESE,
David; c/o Selexis SA, chemin des Aulx 14, 1228 Plan-
les-Ouates (CH). GIROD, Pierre-Alain; c/o Selexis SA,
chemin des Aulx 14, 1228 Plan-les-Ouates (CH).

(74) Agent: IPRIME RENTSCH KAEIN AG; Hirschen-
graben 1, 8001 Zürich (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

(54) Title: TARGETED INTEGRATION IN MAMMALIAN SEQUENCES ENHANCING GENE EXPRESSION




Fig. 1

(57) Abstract: Disclosed are cells that have stably integrated into their genomes exogenous nucleic acid sequences, such as transgenes, within or proximal to the integration site of a sequence comprising at least part of an endogenous retrovirus (ERV) or a LTR-retrotransposon (LTR-RT), or instead of a sequence encompassing an ERV or a LTR-RT that is part or was part of the genome of the cell, as well as method of producing and using such cells. Advantageously, a high level and/or stable production of the transgene expression product(s) can be achieved. Transgene integration and expression may be furthered by modulating the DNA repair pathways of the cell, e.g., by transiently expressing a gene encoding a protein that forms part of a DNA repair pathway during transgene integration.

[Continued on next page]

WO 2021/130718 A1

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))